Kavita Gupta, M.D.

Padmaja Kandula, MD is the Director of the Comprehensive Epilepsy Center at Weill Cornell Medicine. Additionally, she is also the Director of the Clinical Neurophysiology Fellowship at the Weill Cornell Medical College. She received her medical degree at Northeastern Ohio University College of Medicine in Ohio, followed by a residency in neurology at Vanderbilt University Medical Center and two fellowships in Clinical Neurophysiology/Epilepsy and Intraoperative Surgical Monitoring, both at Weill Cornell Medical College. She is certified by The American Board of Psychiatry and Neurology and the American Board of Clinical Neurophysiology. Her major area of interest is epilepsy. Within epilepsy, subspecialty areas of interest include epilepsy surgery and presurgical workup, intensive care neurologic monitoring (ICU monitoring), neuro-oncology and epilepsy, and women's issues and epilepsy.

Michal Bar-Natan, MD, is Associate Professor of Clinical Medicine and a member of the Leukemia Program at Weill Cornell Medicine and NewYork-Presbyterian Hospital in New York City. Dr. Bar-Natan graduated cum laude from the Sackler School of Medicine. She completed her Internal Medicine Residency at Sheba Medical Center and her Fellowship in Hematology and Medical Oncology at NYU Langone Health. In addition to her clinical fellowship training, Dr. Bar-Natan completed a research fellowship at Dana Farber Cancer Institute and Brigham and Women’s Hospital (Harvard Medical School) with a focus on the role that signal transducer and activator of transcription (STAT) proteins play in the development and treatment of myeloproliferative neoplasms (MPNs) and leukemias.Prior to this position Dr. Bar-Natan served as Associate Professor of Medicine at the Icahn School of Medicine at Mt. Sinai, an Attending Physician with the Center of Excellence for Blood Cancers and Myeloid Disorders, and as the leader of the Acute Lymphoblastic Leukemia program at the Mt. Sinai Tisch Cancer Institute. Dr. Bar-Natan’s focus is on translational research in malignant hematology, particularly myeloid malignancies and acute lymphoblastic leukemia, and the development of investigator-initiated clinical trials for patients with these conditions. She leads early phase clinical trials implementing new therapeutic approaches, such as immunotherapies and combination therapies, and serves as the PI and co-investigator on many clinical trials for acute leukemias and myeloproliferative neoplasms.